Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene long-term extension in alcohol dependence
NCT02382276Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nalmefene in alcohol dependence, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Number of Participants With Adverse Events at 24 weeks. Started Jul 2015; status: completed.
02
Drugs
nalmefene
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NCT02382276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382276.